OmniAb, Inc.
.png){kind=logo} | |
| Public | |
| Traded as | Nasdaq: OABI |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | |
| Founder 👔 | |
| Headquarters 🏙️ | , Emeryville, California , United States of America |
Area served 🗺️ | |
| Revenue🤑 | $34.748 million (2021) |
| Members | |
Number of employees | 93 (2022) |
| 🌐 Website | https://www.omniab.com/ |
| 📇 Address | |
| 📞 telephone | |
OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company working in therapeutic antibody discovery. The company became an independent publicly traded company in November 2022 and is headquartered in Emeryville, CA.
OmniAb uses proprietary transgenic animal models, namely OmniRat, OmniMouse, OmniChicken, OmniFlic, and OmniClic, along with technologies like phenotypic screening, bioinformatics, next-generation sequencing (NGS), and functional characterization to provide therapeutic antibodies to other biopharmaceutical companies.[1]
History
In March 2022, OmniAb was created as a new entity after a spin-off from Ligand Pharmaceuticals. OmniAb was then merged into Avista Capital Partners, a publicly traded special purpose acquisition company (SPAC), to form an independent public company on November 1, 2022. The combined company began regular trading on NASDAQ on November 2, 2022, under the ticker symbol OABI.[2]
As of 2023, Matt Foehr is the company's CEO, with Jennifer Cochran, Carolyn Bertozzi, and others on the board of directors.
Research and development
OmniAb has engineered transgenic rodents called OmniRat and OmniMouse. These animals express chimeric antibodies, which are part human and part rodent. The human part is the variable region responsible for recognizing a foreign substance (or antigen), while the rodent part is the constant region.[3][4][5] OmniRat and OmniMouse have their natural rodent antibody genes turned off. As a result, when OmniRat is exposed to an antigen, they produce strong and specific immune responses with high-affinity antibodies like regular rodents found in the wild.[3]
The company has also developed OmniChickens. Chickens are more different from humans than rodents, so when exposed to human antigens, their immune response is more robust and can cover a broader range of targets compared to mice.[6][7][8] The OmniChicken models were modified to make antibodies with human variable and chicken constant regions. These modified chickens show a similar immune system development process and target coverage as regular chickens found in nature.[6][7][8]
OmniFlic and OmniClic, two additional models OmniAb developed, help discover special antibodies that can target two different things inside the body, called bispecific antibodies. The company designed these models to have a fixed light chain, which helps solve a challenge faced by developers in pairing the right components for these dual-targeting antibodies. By using an approach called "knob-in-hole," they can mix and match different light chains with specific heavy chains, resulting in fully human, bispecific antibodies.[9]
The company has two other animal models: OmniTaur, a cow-based antibody discovery system that helps find antibodies with extra-long regions in their heavy chains, and OmnidAb, a chicken-based antibody discovery system for making fully human antibodies that only have heavy chains.
The company’s single B-cell analysis tool, called the gel encapsulated microenvironment (GEM) assay, screens B-cells directly from immunized animals and detects low nanomolar affinities.[10] One of their screening systems, xPloration, uses AI screening to identify antibodies for further development. The system also allows downstream NGS analysis.
Recently, OmniAb launched OmniDeep, which combines computer modeling and artificial intelligence to help drug developers pick the best targets and antibody candidates with the highest chance of treating diseases safely and effectively.
Applications
Zimberelimab, a fully human OmniAb-derived anti-PD-1 monoclonal antibody, was approved by China’s National Medical Products Administration (NMPA) on August 20, 2021. The antibody is used to treat recurrent or refractory classical Hodgkin’s lymphoma.[11]
On October 25, 2022, the Food and Drug Administration approved Tecvayli™ (teclistamab-cqyv), a bispecific T-cell engager antibody for treating adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. Tecvayli was discovered and developed by Janssen Pharmaceuticals using OmniAb’s OmniRat system.[12]
Cejemly® (sugemalimab), an OmniAb-derived anti-PD-L1 monoclonal antibody, is used for the first-line treatment of metastatic (stage IV) non-small cell lung cancer in combination with chemotherapy, as well as for patients with unresectable stage III non-small cell lung cancer. Cejemly® is provided by CStone Pharmaceuticals with approval from the NMPA in China.[13]
OmniAb’s developed antibodies are also used by 65 other companies, including Amgen, Boehringer Ingelheim, Genmab, Merck, Pfizer, Sanofi, and Takeda.
Selected bibliography
OmniAb has presented its research and technology at scientific conferences and published scientific literature, including:
- Immunoglobulin knockout chickens via efficient homologous recombination in primordial germ cells[14]
- Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies[15]
- Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor[16]
- A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3[17]
- V(D)J Rearrangement Is Dispensable for Producing CDR-H3 Sequence Diversity in a Gene Converting Species[18]
- OmniTaur™: Ultralong CDR3 cow antibodies for challenging targets[19]
- Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencing[20]
References
- ↑ "Antibody Discovery Technology". OmniAb. Retrieved 2023-02-03.
- ↑ "Ligand's New Antibody Business Prepares to Hit the Nasdaq". BioSpace. Retrieved 2023-08-07.
- ↑ 3.0 3.1 Osborn, Michael J.; Ma, Biao; Avis, Suzanne; Binnie, Ashleigh; Dilley, Jeanette; Yang, Xi; Lindquist, Kevin; Ménoret, Séverine; Iscache, Anne-Laure; Ouisse, Laure-Hélène; Rajpal, Arvind; Anegon, Ignacio; Neuberger, Michael S.; Buelow, Roland; Brüggemann, Marianne (2013-02-15). "High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region". Journal of Immunology. 190 (4): 1481–1490. doi:10.4049/jimmunol.1203041. ISSN 1550-6606. PMC 3566577. PMID 23303672.
- ↑ Ménoret, Séverine; Iscache, Anne-L.; Tesson, Laurent; Rémy, Séverine; Usal, Claire; Osborn, Michel J.; Cost, Gregory J.; Brüggemann, Marianne; Buelow, Roland; Anegon, Ignacio (9 September 2010). "Characterization of immunoglobulin heavy chain knockout rats". European Journal of Immunology. 40 (10): 2932–2941. doi:10.1002/eji.201040939. PMID 21038471. Unknown parameter
|s2cid=ignored (help) - ↑ Geurts, Aron M.; Cost, Gregory J.; Freyvert, Yevgeniy; Zeitler, Bryan; Miller, Jeffrey C.; Choi, Vivian M.; Jenkins, Shirin S.; Wood, Adam; Cui, Xiaoxia; Meng, Xiangdong; Vincent, Anna; Lam, Stephen; Michalkiewicz, Mieczyslaw; Schilling, Rebecca; Foeckler, Jamie (2009-07-24). "Knockout rats via embryo microinjection of zinc-finger nucleases". Science. 325 (5939): 433. Bibcode:2009Sci...325..433G. doi:10.1126/science.1172447. ISSN 1095-9203. PMC 2831805. PMID 19628861.
- ↑ 6.0 6.1 Ching, Kathryn H.; Collarini, Ellen J.; Abdiche, Yasmina N.; Bedinger, Daniel; Pedersen, Darlene; Izquierdo, Shelley; Harriman, Rian; Zhu, Lei; Etches, Robert J.; van de Lavoir, Marie-Cecile; Harriman, William D.; Leighton, Philip A. (2018-01-02). "Chickens with humanized immunoglobulin genes generate antibodies with high affinity and broad epitope coverage to conserved targets". mAbs. 10 (1): 71–80. doi:10.1080/19420862.2017.1386825. ISSN 1942-0862. PMC 5800366. PMID 29035625.
- ↑ 7.0 7.1 Abdiche, Yasmina Noubia; Harriman, Rian; Deng, Xiaodi; Yeung, Yik Andy; Miles, Adam; Morishige, Winse; Boustany, Leila; Zhu, Lei; Izquierdo, Shelley Mettler; Harriman, William (2015-12-14). "Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms". mAbs. 8 (2): 264–277. doi:10.1080/19420862.2015.1118596. ISSN 1942-0862. PMC 4966639. PMID 26652308.
- ↑ 8.0 8.1 Vuksanaj, Kathy (2019-05-01). "A Therapeutic Antibody Characterization Trinity Accelerates Drug Development". GEN - Genetic Engineering and Biotechnology News. Retrieved 2023-03-01.
- ↑ Gera, Nimish (2022-08-03). "The evolution of bispecific antibodies". Expert Opinion on Biological Therapy. 22 (8): 945–949. doi:10.1080/14712598.2022.2040987. ISSN 1471-2598. PMID 35147061 Check
|pmid=value (help). Unknown parameter|s2cid=ignored (help) - ↑ Mettler Izquierdo, Shelley; Varela, Stephanie; Park, Minha; Collarini, Ellen J.; Lu, Daniel; Pramanick, Shreya; Rucker, Joseph; Lopalco, Lucia; Etches, Rob; Harriman, William (August 2016). "High-efficiency antibody discovery achieved with multiplexed microscopy". Microscopy. 65 (4): 341–352. doi:10.1093/jmicro/dfw014. ISSN 2050-5698. PMC 5895110. PMID 27107009.
- ↑ "Ligand's Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory". Bloomberg.com. 2021-08-30. Retrieved 2023-02-03.
- ↑ "U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma | Johnson & Johnson". Content Lab U.S. Retrieved 2023-02-03.
- ↑ "Ligand's Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly®) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy :: Ligand Pharmaceuticals Incorporated (LGND)". www.ligand.com. Retrieved 2023-02-03.
- ↑ Schusser, Benjamin; Collarini, Ellen J.; Yi, Henry; Izquierdo, Shelley Mettler; Fesler, Jeffrey; Pedersen, Darlene; Klasing, Kirk C.; Kaspers, Bernd; Harriman, William D.; van de Lavoir, Marie-Cecile; Etches, Robert J.; Leighton, Philip A. (2013-12-10). "Immunoglobulin knockout chickens via efficient homologous recombination in primordial germ cells". Proceedings of the National Academy of Sciences of the United States of America. 110 (50): 20170–20175. Bibcode:2013PNAS..11020170S. doi:10.1073/pnas.1317106110. ISSN 1091-6490. PMC 3864345. PMID 24282302.
- ↑ Ouisse, Laure-Hélène; Gautreau-Rolland, Laetitia; Devilder, Marie-Claire; Osborn, Michael; Moyon, Melinda; Visentin, Jonathan; Halary, Frank; Bruggemann, Marianne; Buelow, Roland; Anegon, Ignacio; Saulquin, Xavier (2017-01-09). "Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies". BMC Biotechnology. 17 (1): 3. doi:10.1186/s12896-016-0322-5. ISSN 1472-6750. PMC 5234254. PMID 28081707.
- ↑ Könitzer, Jennifer D.; Pramanick, Shreya; Pan, Qi; Augustin, Robert; Bandholtz, Sebastian; Harriman, Rian; Izquierdo, Shelley (2017-04-03). "Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor". mAbs. 9 (3): 536–549. doi:10.1080/19420862.2016.1276683. ISSN 1942-0862. PMC 5384726. PMID 29494279.
- ↑ Bednenko, Janna; Harriman, Rian; Mariën, Lore; Nguyen, Hai M.; Agrawal, Alka; Papoyan, Ashot; Bisharyan, Yelena; Cardarelli, Joanna; Cassidy-Hanley, Donna; Clark, Ted; Pedersen, Darlene; Abdiche, Yasmina; Harriman, William; van der Woning, Bas; de Haard, Hans (2018-05-19). "A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3". mAbs. 10 (4): 636–650. doi:10.1080/19420862.2018.1445451. ISSN 1942-0862. PMC 5973702. PMID 29494279.
- ↑ Leighton, Philip A.; Morales, Jacqueline; Harriman, William D.; Ching, Kathryn H. (2018). "V(D)J Rearrangement Is Dispensable for Producing CDR-H3 Sequence Diversity in a Gene Converting Species". Frontiers in Immunology. 9: 1317. doi:10.3389/fimmu.2018.01317. ISSN 1664-3224. PMC 6008532. PMID 29951062.
- ↑ Smider, Vaughn. "OmniTaur™: Ultralong CDR3 Cow Antibodies for Challenging Targets" (PDF). Retrieved February 7, 2023.
- ↑ Joyce, Collin; Burton, Dennis R.; Briney, Bryan (2020-01-24). "Comparisons of the antibody repertoires of a humanized rodent and humans by high throughput sequencing". Scientific Reports. 10 (1): 1120. Bibcode:2020NatSR..10.1120J. doi:10.1038/s41598-020-57764-7. ISSN 2045-2322. PMC 6981180 Check
|pmc=value (help). PMID 31980672.
This article "OmniAb" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:OmniAb. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
